TPST
NASDAQTempest Therapeutics
$1.56
+0.00 (+0.00%)
Income Statement
Total Revenue
In Millions USDNet Income
In Millions USDProfit Margins
Gross
Operating
Net
Detailed Income Statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - |
| Cost of Revenue | - | $389K | $381K | $2M | $1M |
| Gross Profit | - | $-389K | $-381K | $-2M | $-1M |
| Operating Expenses | - | - | - | - | - |
| Operating Income | $-27M | $-42M | $-29M | $-35M | $-27M |
| Net Income | $-26M | $-42M | $-29M | $-36M | $-28M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Balance Sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $8M | $30M | $39M | $31M | $52M |
| Total Assets | $17M | $41M | $52M | $46M | $73M |
| Total Liabilities | $10M | $22M | $25M | $28M | $37M |
| Total Debt | $1M | $7M | $12M | $12M | $17M |
| Shareholders Equity | $7M | $19M | $27M | $18M | $36M |
Cash Flow Statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-27M | $-33M | $-27M | $-31M | $-26M |
| Investing Cash Flow | - | $-435K | $-170K | $-562K | $-97K |
| Financing Cash Flow | $4M | $24M | $36M | $11M | $59M |
| Capital Expenditures | - | $435K | $170K | $562K | $135K |
| Free Cash Flow | $-27M | $-33M | $-28M | $-32M | $-26M |